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Background: The management of patients with advanced stages of head and neck cancer requires a
multidisciplinary and multimodality treatment approach which includes a combination of surgery, radiation, and
chemotherapy. These toxic treatment protocols have significantly improved survival outcomes in a distinct
population of human papillomavirus (HPV) associated oropharyngeal cancer. HPV negative head and neck
squamous cell carcinoma (HNSCC) remains a challenge to treat because there is only a modest improvement in
survival with the present treatment regimens, requiring innovative and new treatment approaches. Oncolytic
viruses used as low toxicity adjunct cancer therapies are novel, potentially effective treatments for HNSCC. One such
oncolytic virus is Respiratory Orphan Enteric virus or reovirus. Susceptibility of HNSCC cells towards reovirus
infection and reovirus-induced cell death has been previously demonstrated but has not been compared in HPV
positive and negative HNSCC cell lines.
Objectives: To compare the infectivity and oncolytic activity of reovirus in HPV positive and negative HNSCC cell
lines.
Methods: Seven HNSCC cell lines were infected with serial dilutions of reovirus. Two cell lines (UM-SCC-47 and
UM-SCC-104) were positive for type 16 HPV. Infectivity was measured using a cell-based ELISA assay 18 h after
infection. Oncolytic activity was determined using an alamar blue viability assay 96 h after infection. Non-linear
regression models were used to calculate the amounts of virus required to infect and to cause cell death in 50% of
a given cell line (EC50). EC50 values were compared.
Results: HPV negative cells were more susceptible to viral infection and oncolysis compared to HPV positive cell
lines. EC50 for infectivity at 18 h ranged from multiplicity of infection (MOI) values (PFU/cell) of 18.6 (SCC-9) to 3133
(UM-SCC 104). EC50 for cell death at 96 h ranged from a MOI (PFU/cell) of 1.02×10
2 (UM-SCC-14A) to 3.19×108
(UM-SCC-47). There was a 3×106 fold difference between the least susceptible cell line (UM-SCC-47) and the most
susceptible line (UM-SCC 14A) EC50 for cell death at 96 h.
Conclusions: HPV negative HNSCC cell lines appear to demonstrate greater reovirus infectivity and virus-mediated
oncolysis compared to HPV positive HNSCC. Reovirus shows promise as a novel therapy in HNSCC, and may be of
particular benefit in HPV negative patients.
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Head and neck squamous cell carcinoma (HNSCC) is a
devastating disease that affects all aspects of the patient’s
life, even in survivorship [1]. The management of pa-
tients with advanced stages of this disease requires a
multidisciplinary and multimodality treatment approach
which includes a combination of surgery, radiation, and
chemotherapy. These toxic treatment protocols have sig-
nificantly improved survival outcomes, especially in a
distinct population of human papillomavirus (HPV) as-
sociated oropharyngeal cancer [2-7]. HPV is an import-
ant risk factor for a subset of HNSCC [8-10] and types
16 and 18 are particularly high risk for oncogenic trans-
formation [11]. Patients with HPV associated head and
neck cancer tend to be younger and less likely to have a
significant history of smoking and alcohol consumption
in comparison to those affected by non-HPV related
head and neck cancer [8,12]. Advanced stage HPV
negative HNSCC remains a challenge to treat because
there is only a modest improvement in survival out-
comes despite advances in therapy and the increasing
toxicity of the different protocols [2,4-6]. This subset
of patients, therefore, requires innovative and new
treatment approaches.
The use of oncolytic viruses as a low toxicity adjunct
cancer therapy is a novel and potentially effective treat-
ment for HNSCC. One such oncolytic virus is Respira-
tory Orphan Enteric virus or reovirus [13-18]. Reovirus,
from the family Reoviridae, is a non-enveloped, double
stranded RNA virus that infects the upper respiratory
and gastrointestinal tracts of humans with minimal
symptoms [19]. Reovirus shows potent anti-tumor activ-
ity in a variety of tumor models, including models of
HNSCC [20-27]. Multiple mechanisms mediate the
strong specificity of reovirus towards cancer cells and es-
pecially towards cells with activated Ras signalling
[16,28-33]. A proprietary formulation of the type 3 Dearing
reovirus strain, called Reolysin®, is undergoing numerous
phase I and phase II clinical trials and is currently in a
phase III trial [19,34,35].
Susceptibility of HNSCC cells towards reovirus infec-
tion and reovirus-induced cell death has been previously
demonstrated in both in vitro and mouse models
[22,26,36,37], but the effectiveness and infectivity of reo-
virus in HPV positive and negative head and neck cancer
cell lines has not been examined. The objectives of this
study were to compare the infectivity and oncolysis of
reovirus in HPV positive and negative HNSCC cell lines.
Methods
Cell lines
SCC-9, SCC-25, FaDU and L929 were purchased from
ATC and maintained according to instructions. UM-
SCC-14A, UM-SCC-38, UM-SCC-47, and UM-SCC-104were obtained from Dr. Thomas Carey at the University of
Michigan and maintained according to instructions. UM-
SCC-47 and UM-SCC-104 are both positive for high risk
HPV 16 and express viral proteins E6 and E7 [38-40].
Virus
Reovirus serotype 3 Dearing was propagated in L929
cells and purified by ultracentrifugation on cesium chlor-
ide (CsCl) gradients as previously described [41]. Virus-
infected cells were freeze-thawed and twice extracted with
Vertrel XF (Dymar Chemicals) as previously described
[41] and then layered onto 1.25- to 1.45-g/ml CsCl gradi-
ents. Virus was banded at 23,000 rpm for 5 h and dialyzed
extensively against virus dilution buffer (150 mM NaCl,
15 mM MgCl2, 10 mMTris, pH 7.4). Titers of purified
reovirus preparations were obtained using standard plaque
titration on L929 cells, and expressed as plaque forming
units (PFU) per millilitre [32].
Seeding and infection of cells
Cells were counted using a TC20 automated cell counter
(BioRad). 125 μL of cells at a concentration of 2.5×105 cells/
mL were seeded into each well of a 96 well plate to
achieve 100% confluence at time of infection. Serial dilu-
tions of reovirus serotype 3 Dearing ranging from 4.8×108
to 1.43×101 PFU/mL (relative to L929 cells) were prepared
in minimal essential media (MEM). Cells were incubated
with 50 μl of virus at 37°C for 1 hour, then returned to
virus-free complete medium for the remaining incubation
period under standard tissue culture conditions.
Cell-based ELISA assay for infectivity
Eighteen hours after infection, cells were washed with
PBS, fixed with methanol, and stored in blocking solu-
tion (Bovine serum albumin, PBS, Triton X-100). Cells
were incubated with rabbit anti-reovirus primary anti-
body (1:5000, blocking solution), washed with PBS-T
(PBS, Triton X-100) solution, then incubated with goat
anti-rabbit alkaline phosphatase antibody (1:4000, block-
ing solution). Following extensive washes with PBS-T,
200 μL of P-nitrophenyl phosphate in diethanolamine
buffer (1 mg/mL) was added to each well. Plates were in-
cubated at room temperature for 80 minutes, and absorb-
ance was measured at 405 nm using a spectrophotometer
(EnVision Multilabel Reader, Perkin Elmer).
Alamar blue viability assay
Alamar blue is a commonly used indicator in cell viability
assays [42]. At 96 hours after infection, 20 μL of 440 μM
alamar blue in sterile PBS diluted 1:10 with ddH2O was
added to each well of a 96-well plate. Following incubation
for 2 hours at 37°C, fluorescence was measured at excitation/
emission wavelengths of 544/590 nm respectively (Fluostar
OPTIMA plate reader, BMG Labtech).
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Using the measured fluorescence from the alamar blue
assay, viability at 96 h was calculated in the well infected
with reovirus at a concentration of 2.40×108 PFU/mL.
Fluorescence was averaged from two or more duplicates
within each experiment. Viability was expressed as a per-
centage with 100% viability determined by the fluores-
cence of the uninfected cells and 0% viability calculated
as an average of the fluorescence of wells containing
media but not seeded with cells. Mean viability was cal-
culated for each cell line from three or more independ-
ent experiments. Statistically significant outliers and
experiments with technical issues related to uneven
seeding of cells were excluded from analysis.Calculation of EC50 values
Effective concentration 50 or EC50 is a term used in
pharmacodynamics indicating the concentration re-
quired to have a 50% maximal effect. In the context of
infection with a virus, we have defined EC50 to indicate
the amount of virus needed to infect 50% of cells at
18 hours postinfection, as measured by a cell-based
ELISA assay. To quantify reovirus-induced cell death,
we have defined EC50 to indicate the amount of virus re-
quired to reduce cell viability to 50% (relative to un-
treated cells) at 96 hours postinfection, as measured by
an alamar blue viability assay. Absorbance (infectivity)
or fluorescence (cell viability) values were plotted against
multiplicity of infection (MOI, PFU/cell). Baseline and
maximum response were established from uninfected
cells (maximum viability, minimum infectivity), media
alone (minimum viability), or maximally-infected L929
cells (maximum infectivity). Mean absorbance or fluor-
escence at a given viral concentration was calculated as
the mean of two or more duplicates within the same ex-
periment. Three or more independent experiments were
used to generate a dose–response curve for each cell line
(Prism; Graph-Pad Software Inc., San Diego, CA). From
this, EC50 values were calculated by fitting a standard
equation for a sigmoidal dose–response curve.Statistical analysis
Student’s t-test was used to compare EC50 values for in-
fectivity and oncolysis between cell lines. Student’s t-test
was also used to compare cell viability at 96 h. P < 0.05
was accepted as statistically significant.Figure 1 EC50 values for infection by reovirus after 18 h of
various HPV negative and positive HNSCC cell lines. Error bars
represent standard deviation.Ethics
Institutional ethics review board approval was obtained
from the University of Alberta Health Research Ethics
Board prior to the commencement of the study.Results
Infectivity
EC50 MOI for infectivity at 18 h indicates the number of
reovirus particles per cell that were sufficient to achieve
infection and active replication in 50% of cells at this
time point. The HNSCC cell lines demonstrated variable
susceptibility to infection by reovirus at 18 h. The cell
lines listed from most to least susceptible to reovirus in-
fection at 18 h and their corresponding EC50 MOI values
(PFU/cell) were SCC-9 (18.6 ± 0.7), FaDU (28.4 ± 0.7),
SCC-25 (51.2 ± 1.6), UM-SCC-14A (77.3 ± 3.1), UM-
SCC-38 (651 ± 11), UM-SCC-47 (1425 ± 23), and UM-
SCC-104 (3133 ± 86) (Figure 1). The most susceptible
HNSCC cell lines were SCC-9 and FaDU. These cell
lines required a mean of 18.6 and 28.4 virus particles per
cell to achieve 50% infectivity at 18 h respectively. The
least susceptible cell lines, UM-SCC-47 and UM-SCC-
104, were both HPV positive. They required a mean of
1425 and 3133 virus particles per cell to achieve 50% in-
fection, respectively. In comparing the two HPV positive
cell lines individually to each of the 5 HPV negative cell
lines, the HPV positive HNSCC cell lines were less sus-
ceptible to infection by reovirus with statistical signifi-
cance (p < 0.01).
96 h viability
Differences in percent viability were also found between
cell lines 96 h after infection with reovirus at a concentra-
tion of 2.40x108 PFU/mL. This equates to an MOI of
7.68×103 viral particles per cell. The mean percent viabil-
ities for each cell line from least to greatest were UM-SCC-
14A (6.7 ± 5.0%), FaDU (10.9 ± 3.7%), SCC-9 (33.2 ± 9.9%),
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UM-SCC-38 (83.9 ± 16.3%), and UM-SCC-47 (97.2 ± 4.7%)
(Figure 2). The two most susceptible cell lines to virally-
induced cytotoxicity were UM-SCC-14A and FaDU which
were both HPV negative. Of the three cell lines with the
greatest viability at this time point, two were HPV positive
(UM-SCC-104 and UM-SCC-47). UM-SCC-47 had more
viable cells with statistical significance than all of the HPV
negative cell lines except for UM-SCC-38 (p = 0.17). UM-
SCC-104 had more viable cells with statistical significance
than UM-SCC-14A, FaDU, and SCC-9 (all with p < 0.01).
The HPV positive cell lines were highly resistant to onco-
lysis by reovirus and showed only minimal viral-induced
cytotoxicity at 96 h, even with high concentrations of reo-
virus used for infection. Images taken from brightfield mi-
croscopy at 96 hours after infection of the UM-SCC-14A,
UM-SCC-47, and UM-SCC-104 cell lines demonstrate this
difference (Figure 3).
Oncolysis
The head and neck cancer cell lines had variable EC50
values for cell death at 96 h. The HNSCC cell line most
susceptible to reovirus was UM-SCC-14A (HPV nega-
tive) with a mean EC50 MOI (PFU/cell) value of 102
(95%CI [93–112]). This means that 102 reovirus parti-
cles per cell were sufficient to cause 50% cell death in
this cell line. The remaining cell lines from most to least
susceptible to reovirus-mediated oncolysis and their cor-
responding EC50 MOI (PFU/cell) values were FaDU
(388, CI[378–397]), SCC-9 (4.24×103, CI[4.00×103–
4.49×103]), SCC-25 (1.07×104, CI[1.03×104–1.10×104]),Figure 2 Percentage of viable cells of various HNSCC cell lines
96 h after addition of 2.40×108 PFU/mL dilution of reovirus.
Mean values were taken from three or more independent experiments.
Error bars represent standard deviation.UM-SCC-38 (2.99×104, CI[2.80×104–3.18×104]), UM-
SCC-104 (4.04×105, CI[2.62×105–6.23×105]), and UM-
SCC-47 (3.19×108, CI[1.31×108–7.76×108) (Figure 4).
The two HPV positive cell lines were more resistant to
reovirus-mediated oncolysis in comparison to the HPV
negative cell lines (p < 0.01 in all cases).
Discussion
The use of viruses in cancer therapy is a rapidly expand-
ing area of research [13,16,23,27,34]. However, the use of
viral oncolytic therapy has yet to make the transition
from bench to bedside in standard practice. Reovirus
was first shown to have an oncolytic effect in head and
neck cancer cells by Ikeda et al. [22] using in vitro and
in vivo models. This effect has been demonstrated in nu-
merous head and neck cell lines [24,25,36,37]. The onco-
lytic effect is believed to be independent of epidermal
growth factor receptor (EGFR) activation and molecular
predictors of response have yet to be identified [25]. Pre-
clinical studies have shown the effectiveness of a com-
bination of reovirus, paclitaxel and cisplatin in head and
neck cancer lines [24]. Also, animal models have sug-
gested a role for reovirus as an adjunct in surgically
resected disease with positive margins [37]. Intravenously
administered reovirus in combination with carboplatin
and paclitaxel has been shown to have activity in advanced
stage and recurrent head and neck cancer in a recently
published phase I/II clinical trial [35]. An ongoing phase
III trial is investigating intravenous reovirus in combin-
ation with paclitaxel and carboplatin (Reo 018).
Reovirus has variable infectivity and oncolytic activity
in head and neck cancer cell lines and the mechanism
behind this variable susceptibility has yet to be eluci-
dated but is likely multifactorial. Our findings suggest an
important difference in the susceptibility of head and
neck cancer cells to reovirus based on HPV status. The
HPV negative cell lines used were much more suscep-
tible than the HPV positive cells to both infection by
reovirus and virus-mediated oncolysis. There was a >150
fold difference in the amount of virus required to infect
50% of cells in the most susceptible cell line (SCC-9)
and the least susceptible cell line (UM-SCC-104). Simi-
larly, there was a dramatic difference between oncolysis
based on HPV status. There was a 3x106 fold difference
in the EC50 values of the most susceptible cell line UM-
SCC-14A (HPV negative) and the most resistant cell line
UM-SCC-47 (HPV positive). For both infectivity at 18 h
and oncolysis at 96 h, the HPV negative cells were more
susceptible than the HPV positive cells by highly signifi-
cant values. Our study is the first to compare the onco-
lytic activity of reovirus in HPV positive and negative
head and neck cancer cell lines. Also, it is the first to
compare reovirus infectivity among head and neck can-
cer cell lines.
Figure 3 Brightfield microscopy of UM-SCC-14A, UM-SCC-47, and UM-SCC-104 cells 96 h after the addition of 4.8×108 and 2.4×108
PFU/mL reovirus dilutions according to experiment protocol compared to uninfected controls
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cell carcinoma (OPSCC) has been shown to have a more
favourable response to treatment with surgical and non-
surgical treatments [6,7]. However, when considering
treatment with cetuximab, a monoclonal antibody that
targets EGFR, a number of studies suggest HPV positive
OPSCC tumors may be less responsive to this chemo-
therapeutic drug [43,44]. This is consistent with several
studies showing an inverse relationship with HPV posi-
tivity [44]. It is important to note that both reovirus andFigure 4 EC50 values for oncolysis 96 h after reovirus infection
of various HPV negative and positive HNSCC cell lines. Error
bars represent standard deviation.cetuximab act on Ras-dependent pathways [44]. Taken
together, our results showing resistance to reovirus in
HPV-positive HNSCC cell lines could therefore be due
to a lack of EGFR expression and its downstream Ras-
dependent treatment response.
Novel therapies are needed in head and neck cancer,
especially in patients with HPV negative malignancies.
Conventional therapy is associated with substantial mor-
bidity and long-term complications [1], and progress has
been limited in the use of adjuvant therapy in patients
with advanced stage HPV negative cancers [45]. Reo-
virus shows promise as a potential novel therapy in HPV
negative head and neck cancer.
Further research is required to identify additional mo-
lecular markers for susceptibility to reovirus to identify
patients most likely to benefit from adjunctive reovirus
therapy. HPV negative patients, a group with a poor
prognosis relative to those with HPV-related head and
neck cancer, are identified as a group to target in future
reovirus trials. Ongoing and future trials investigating
reovirus in head and neck cancer may need to perform
subgroup analysis based on HPV status.
Commonly described features of HNSCC cell lines in-
clude tumor subsite, staging, and treatment modalities
utilized. Although clinically relevant, the smoking his-
tory of the patients from which these cell lines have been
derived is not well described in the literature. The smok-
ing status of the patients from which FaDU and SCC-9
were derived is not documented. The source of SCC-25
had an extensive history of smoking [46]. Of the cell
lines obtained from Dr. Carey and the University of
Michigan, UM-SCC-14A, UM-SCC-38, and UM-SCC-
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no laboratory documentation regarding the smoking sta-
tus of the patient from which the HPV positive UM-
SCC-47 cell line was derived. Despite this limitation in
clinical history, numerous papers have delineated geno-
typic differences between these and other HNSCC cell
lines [48].
There are several limitations to this study. The behav-
ior of cell lines in in vitro experiments is variable. Con-
founding factors between the cell lines used beyond
HPV status may have an impact on results. Head and
neck cancer is a molecularly and genetically heteroge-
neous entity [48,49]. Therefore, caution must be used in
generalizing the effect of reovirus on a selection of cell
lines to all HPV positive or negative head and neck can-
cers. However, this study design allowed for a time and
cost efficient way to test a hypothesis regarding the ac-
tivity of reovirus and HPV positive and negative head
and neck cancers. Further investigation into the effect of
reovirus on additional HPV positive and negative cell
lines as well as in HPV positive and negative animal
models is warranted.
Conclusions
HPV negative cell lines appear to be more susceptible to
reovirus infection and oncolysis than their HPV positive
counterparts. Reovirus shows promise as a potential
novel therapy in HPV negative head and neck cancer.
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